UY31418A1 - Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos - Google Patents
Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivosInfo
- Publication number
- UY31418A1 UY31418A1 UY31418A UY31418A UY31418A1 UY 31418 A1 UY31418 A1 UY 31418A1 UY 31418 A UY31418 A UY 31418A UY 31418 A UY31418 A UY 31418A UY 31418 A1 UY31418 A1 UY 31418A1
- Authority
- UY
- Uruguay
- Prior art keywords
- preparation
- treatment
- cognitive disorders
- patients affected
- human albumin
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 102000008100 Human Serum Albumin Human genes 0.000 title abstract 2
- 108091006905 Human Serum Albumin Proteins 0.000 title abstract 2
- 208000010877 cognitive disease Diseases 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invencion se basa en la utilizacion de albumina humana terapéutica para la preparacion de un medicamento par el tratamiento de pacientes afectados por desordenes cognitivos, en la que el modelo de administracion del medicamento comprende la administracion al paciente de un mínimo de tres veces sucesivas, de una cantidad terapéuticamente efectiva de albumina terapéutica humana mediante recambio plasmático y/o perfusion intravenosa, sin dependencia del contenido de AB(Beta) en sangre del paciente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200702831A ES2332846B1 (es) | 2007-10-26 | 2007-10-26 | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY31418A1 true UY31418A1 (es) | 2009-05-29 |
Family
ID=40583637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY31418A UY31418A1 (es) | 2007-10-26 | 2008-10-23 | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7851446B2 (es) |
| EP (1) | EP2111868B1 (es) |
| JP (1) | JP5437619B2 (es) |
| CN (1) | CN101417123B (es) |
| AR (1) | AR068901A1 (es) |
| AU (1) | AU2008233025B8 (es) |
| BR (1) | BRPI0804623B8 (es) |
| CA (1) | CA2641830C (es) |
| CL (1) | CL2008003133A1 (es) |
| ES (2) | ES2332846B1 (es) |
| MX (1) | MX2008013635A (es) |
| NZ (1) | NZ572131A (es) |
| PL (1) | PL2111868T3 (es) |
| PT (1) | PT2111868E (es) |
| RU (1) | RU2414925C2 (es) |
| UY (1) | UY31418A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10112000B2 (en) | 2010-07-08 | 2018-10-30 | Asahi Kasei Medical Co., Ltd. | Method for reducing amyloid beta concentration in blood |
| US11103530B2 (en) | 2018-10-26 | 2021-08-31 | Alkahest, Inc. | Methods of improving or accelerating postoperative recovery |
| DK3484502T3 (da) * | 2016-08-18 | 2021-10-25 | Alkahest Inc | Blodplasmafraktioner til behandling mod aldersrelaterede kognitive forstyrrelser |
| EA039316B1 (ru) * | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
| IL270125B2 (en) | 2017-04-26 | 2024-02-01 | Alkahest Inc | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| MX2021000707A (es) * | 2018-07-20 | 2021-03-25 | Alkahest Inc | Regimen de dosificacion para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre. |
| EP3643319A1 (en) * | 2018-10-25 | 2020-04-29 | Grifols Worldwide Operations Limited | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
| JP2023547479A (ja) | 2020-10-30 | 2023-11-10 | シェンチェン、プロトゲン、リミテッド | 疾患の治療におけるヒト血清アルブミンの使用 |
| AU2022267051A1 (en) * | 2021-04-30 | 2023-10-26 | Grifols Worldwide Operations Limited | Use of therapeutic plasma exchange and low volume plasma exchange for the treatment of a cognitive impairment |
| WO2025230830A1 (en) | 2024-04-29 | 2025-11-06 | Alkahest, Inc. | Compositions of blood plasma fractions and their use in treatment of spinal muscular atrophy (sma) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3612137A1 (de) * | 1986-04-10 | 1987-10-15 | Biotest Pharma Gmbh | Steriles plasmaaustauschmittel |
| US5112298A (en) | 1990-06-25 | 1992-05-12 | Baxter International Inc. | Apheresis method and device |
| US5178603A (en) | 1990-07-24 | 1993-01-12 | Baxter International, Inc. | Blood extraction and reinfusion flow control system and method |
| US6627151B1 (en) * | 1997-06-13 | 2003-09-30 | Helmut Borberg | Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion |
| AU2001264801A1 (en) | 2000-05-23 | 2001-12-03 | The University Of Southern California | Diagnosis of alzheimer's disease ldl receptor protein-1 |
| WO2002078670A1 (en) * | 2001-03-02 | 2002-10-10 | Neuron Therapeutics, Inc. | Neuroprotectants formulations and methods |
| AU2002366355A1 (en) | 2001-12-17 | 2003-06-30 | New York State Office Of Mental Health | SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES |
| BR0315008A (pt) | 2002-10-04 | 2005-08-09 | Prana Biotechnology Ltd | Compostos neurologicamente ativos |
| AU2003303198A1 (en) * | 2002-12-19 | 2004-07-14 | New York University | Method for treating amyloid disease |
| CN100384471C (zh) | 2003-02-13 | 2008-04-30 | 奥克塔法马股份有限公司 | 白蛋白溶液及其制备方法 |
| WO2005065069A2 (en) | 2003-07-11 | 2005-07-21 | Myriad Genetics, Inc. | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
| AT413336B (de) * | 2003-09-12 | 2006-02-15 | Mattner Frank Dr | Apherese-vorrichtung |
| US20050182044A1 (en) | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| AT500483B1 (de) | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| RU2281090C2 (ru) * | 2004-09-23 | 2006-08-10 | Алексей Владимирович Смирнов | Способ лечения больных хронической почечной недостаточностью |
| RU2261702C1 (ru) * | 2004-09-23 | 2005-10-10 | Смирнов Алексей Владимирович | Способ лечения гипергомоцистеинемии у больных с хронической почечной недостаточностью, получающих лечение гемодиализом или гемофильтрацией |
| US7436304B1 (en) | 2005-07-19 | 2008-10-14 | Visible Assets, Inc | Evidence tracking |
-
2007
- 2007-10-26 ES ES200702831A patent/ES2332846B1/es not_active Expired - Fee Related
-
2008
- 2008-10-17 AR ARP080104523A patent/AR068901A1/es unknown
- 2008-10-17 RU RU2008141076/15A patent/RU2414925C2/ru active
- 2008-10-17 NZ NZ572131A patent/NZ572131A/en unknown
- 2008-10-22 PT PT83803015T patent/PT2111868E/pt unknown
- 2008-10-22 EP EP08380301.5A patent/EP2111868B1/en active Active
- 2008-10-22 ES ES08380301T patent/ES2428698T3/es active Active
- 2008-10-22 PL PL08380301T patent/PL2111868T3/pl unknown
- 2008-10-23 UY UY31418A patent/UY31418A1/es not_active Application Discontinuation
- 2008-10-23 BR BRPI0804623A patent/BRPI0804623B8/pt active IP Right Grant
- 2008-10-23 MX MX2008013635A patent/MX2008013635A/es active IP Right Grant
- 2008-10-23 CL CL2008003133A patent/CL2008003133A1/es unknown
- 2008-10-23 CN CN2008101705786A patent/CN101417123B/zh active Active
- 2008-10-24 JP JP2008274076A patent/JP5437619B2/ja active Active
- 2008-10-24 US US12/257,814 patent/US7851446B2/en active Active
- 2008-10-24 CA CA2641830A patent/CA2641830C/en active Active
- 2008-10-24 AU AU2008233025A patent/AU2008233025B8/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2008141076A (ru) | 2010-04-27 |
| US7851446B2 (en) | 2010-12-14 |
| CA2641830C (en) | 2013-07-16 |
| CA2641830A1 (en) | 2009-04-26 |
| AU2008233025B2 (en) | 2013-06-27 |
| CL2008003133A1 (es) | 2009-08-07 |
| NZ572131A (en) | 2010-06-25 |
| PT2111868E (pt) | 2013-10-17 |
| BRPI0804623B1 (pt) | 2020-02-11 |
| US20090111740A1 (en) | 2009-04-30 |
| HK1126689A1 (en) | 2009-09-11 |
| ES2428698T3 (es) | 2013-11-08 |
| RU2414925C2 (ru) | 2011-03-27 |
| BRPI0804623B8 (pt) | 2021-05-25 |
| JP5437619B2 (ja) | 2014-03-12 |
| AU2008233025B8 (en) | 2013-07-25 |
| EP2111868B1 (en) | 2013-08-21 |
| CN101417123B (zh) | 2012-06-27 |
| EP2111868A1 (en) | 2009-10-28 |
| AR068901A1 (es) | 2009-12-16 |
| CN101417123A (zh) | 2009-04-29 |
| MX2008013635A (es) | 2009-05-11 |
| AU2008233025A1 (en) | 2009-05-14 |
| ES2332846A1 (es) | 2010-02-12 |
| BRPI0804623A2 (pt) | 2009-06-30 |
| PL2111868T3 (pl) | 2014-01-31 |
| JP2009108059A (ja) | 2009-05-21 |
| ES2332846B1 (es) | 2010-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY31418A1 (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos | |
| Moszczynska et al. | Molecular, behavioral, and physiological consequences of methamphetamine neurotoxicity: implications for treatment | |
| MX2017011280A (es) | Terapia neuro-afectiva regional topica con cannabinoides. | |
| BRPI0820800A2 (pt) | Dispositivo médico implantável para liberação controlada de droga, e, métodos para administração de uma droga na bexiga de um paciente e para tratar a bexiga em um paciente | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| WO2008067991A3 (en) | Skin-friendly drug complexes for transdermal administration | |
| JP2010518164A5 (es) | ||
| AR054249A1 (es) | Tratamiento de enfermedades del tejido conectivo de la piel | |
| EP2424536A4 (en) | NEW PHOTOSENSIBILIZER FORMULATIONS FOR ORAL ADMINISTRATION | |
| AR041891A1 (es) | Empleo de resveratrol para la preparacion de un medicamento util para el tratamiento de infecciones causadas por el virus de la influenza | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| JP2016504361A5 (es) | ||
| Nordal | Where has all the psychotherapy gone? | |
| CN102846684B (zh) | 一种治疗骨刺的药物 | |
| Periyasami et al. | Attai Vidal (Leech Therapy) in Siddha System of Medicine and their current concept in therapeutic application-A Review | |
| Baxtiyarovich et al. | BENEFITS AND SIDE EFFECTS OF MEDICATIONS | |
| SAKHAROVA et al. | PHARMACEUTICAL CARE IN THE TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTIONS: THE PHYTONEERING POSSIBILITIES FROM THE PERSPECTIVE OF EVIDENCE-BASED MEDICINE | |
| Cohen et al. | Mebaral in the treatment of epilepsy | |
| JP1720531S (ja) | 薬液投与器用穿刺具 | |
| Almomani | The effect of ketamine on blood pressure, heart rate, respiratory rate and intraocular pressure in patients undergoing ocular procedures | |
| Fikri-Benbrahim et al. | Effect of pharmaceutical intervention on medication adherence and blood pressure control in treated hypertensive patients: Rationale, design and methods of the AFenPA pilot study | |
| JP1720477S (ja) | 薬液投与器用穿刺具 | |
| JP1720529S (ja) | 薬液投与器用穿刺具 | |
| CN2605869Y (zh) | 冠心病外用药物护胸袋 | |
| Van Schoor | Colds, flu and coughing: a review of over-the-counter nasal therapies in general practice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20190715 |